Federica Perrone
Overview
Explore the profile of Federica Perrone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
3108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bozzi F, Conca E, Silvestri M, Dagrada G, Ardore A, Penso D, et al.
Sci Rep
. 2025 Feb;
15(1):4314.
PMID: 39910096
Copy number alterations (CNAs) play a fundamental role in cancer development and constitute a potential tool for tailored treatments. The CNAs recognition in formalin fixed paraffin embedded (FFPE) material for...
2.
Colombo C, Hakkesteegt S, Cesne A, Barretta F, Blay J, Grunhagen D, et al.
Clin Cancer Res
. 2024 Dec;
31(3):603-610.
PMID: 39620931
Purpose: Three prospective observational studies (Italy, the Netherlands, and France) on active surveillance (AS) in patients with extra-abdominal desmoid-type fibromatosis support AS as a first-line approach. Identifying prognostic factors for...
3.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al.
Cancer Med
. 2024 Dec;
13(23):e70393.
PMID: 39618336
Background: The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6-methylguanine-DNA methyltransferase (MGMT) silencing may occur in a subset of PAC...
4.
Micolonghi C, Perrone F, Fabiani M, Caroselli S, Savio C, Pizzuti A, et al.
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337275
Hereditary cardiomyopathies (CMPs), including arrhythmogenic cardiomyopathy (ACM), dilated cardiomyopathy (DCM), and hypertrophic cardiomyopathy (HCM), represent a group of heart disorders that significantly contribute to cardiovascular morbidity and mortality and are...
5.
Azzollini J, Capone I, Duca M, Vingiani A, Piccolo A, Agnelli L, et al.
Tumori
. 2024 Sep;
:3008916241280127.
PMID: 39311051
Introduction: Tumour /2 sequencing has progressively increased along with the expanding indications for poly(ADP-ribose) polymerase inhibitors. In our study, we investigated the feasibility and outcomes of a workflow for the...
6.
Bergamaschi L, Zorza M, Rini F, Perrone F, Rivoltini L, Gronchi A, et al.
Ann Surg Oncol
. 2024 Sep;
31(13):9265-9271.
PMID: 39244517
Background: Sporadic desmoid fibromatosis (DF) is a rare locally aggressive tumor characterized by mutation in exon 3 of CTNNB1 (T41A, S45F, and S45P). Standard of care is active surveillance (AS),...
7.
Paciello I, Pierleoni G, Pantano E, Antonelli G, Pileri P, Maccari G, et al.
Cell Rep
. 2024 Aug;
43(9):114645.
PMID: 39207904
Understanding the evolution of the B cell response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is fundamental to design the next generation of vaccines and therapeutics. We longitudinally...
8.
Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, et al.
Eur J Cancer
. 2024 Aug;
209:114276.
PMID: 39128186
Background: Metastatic Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors characterized by high morbidity and limited systemic treatment options, mainly based on radiometabolic treatments or chemotherapy. Based on the preclinical...
9.
Paciello I, Maccari G, Pierleoni G, Perrone F, Realini G, Troisi M, et al.
Sci Immunol
. 2024 Aug;
9(98):eadp9279.
PMID: 39121195
The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain...
10.
Serafini M, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38290766
Background: Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit...